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Apriliana Cahya Khayrani1, Md Jahangir Alam1, Juan Du1, Akimasa Seno6, Yoshiaki Iwasaki7 and Masaharu Seno1,4,6
BACKGROUND: Liver cancer is the second most common cause of cancer-related death. Every type of tumours including liver
cancer contains cancer stem cells (CSCs). To date, the molecular mechanism regulating the development of liver CSCs remains
unknown.
METHODS: In this study, we tried to generate a new model of liver CSCs by converting mouse induced pluripotent stem cells
(miPSCs) with hepatocellular carcinoma (HCC) cell line Huh7 cells conditioned medium (CM). miPSCs treated with CM were injected
into the liver of BALB/c nude mice. The developed tumours were then excised and analysed.
RESULTS: The primary cultured cells from the malignant tumour possessed self-renewal capacity, differentiation potential and
tumorigenicity in vivo, which were found rich in liver cancer-associated markers as well as CSC markers.
CONCLUSIONS: We established a model of liver CSCs converting from miPS and showed different stages of stemness during
conversion process. Our CSC model will be important to assess the molecular mechanisms necessary to develop liver CSCs and
could help in defeating liver cancer.
British Journal of Cancer (2020) 122:1378–1390; https://doi.org/10.1038/s41416-020-0792-z
BACKGROUND
According to the World Cancer Report, the incidence of liver
cancer was globally 6% and the mortality burden was 9%.1 With
the number of deaths estimated as 746,000 in 2012, liver cancer is
the second leading cause of cancer mortality in the world. The
liver cancer in men is described as the fifth most common cancer
(554,000 new cases, 8% of the total) and that in women the ninth
(228,000 cases, 3% of the total). Among the primary liver cancers,
hepatocellular carcinoma (HCC) is the major histological subtype.2
Hepatocarcinogenesis could be explained by a complexed multi-
step process at molecular level giving various diagnostic observa-
tions in cells and histology. Although the molecular mechanism of
the liver cancer development has been studied for many years,
these studies focussed only on the cancer cells, which are present
in the cancer tissues, but not the origin of these cancer cells,
which are known as the liver cancer stem cells (CSCs). Liver CSCs
are described with the capacity of self-renewal and differentiation
potential.3 Liver CSCs are currently considered as a specific
subpopulation with significant tumorigenic potential, which
should contribute to the development and recurrence of HCC.4
Taking the presence of original cells as granted, we support the
idea that the liver CSCs could be originated by the transformation
of liver stem/progenitor cells.5 Actually, liver CSCs are identified by
self-renewal and pluripotency and classified with normal liver
stem cell markers.
Generally, CSCs are defined by self-renewal, pluripotency and
tumorigenicity, which play a critical role in the growth of primary
tumours with heterogeneity.6 Considering that CSCs are respon-
sible for the malignant tumorigenic potential providing the
heterogeneity,7 CSCs could be the cells at the top of the hierarchy
undergoing differentiation into cancer cells with diverse pheno-
types with limited proliferative potential in many cancers as found
in the hierarchy of normal stem cells in normal tissues.
Incredible efforts have been made to understand where the
CSCs come from. Owing to the recent rapid progress in the stem
cell research, cancer is widely accepted as a stem cell disease.8
Also, some scientists suggested that hierarchically organised
tumours originated from normal stem cells,9 which opened the
possibility of the liver stem cells to be the origin of liver CSCs.10
Stem cells were hypothesised to dwell in a specific microenviron-
ment called a “stem cell niche”, which plays an essential role to
regulate stem cell maintenance and self-renewal by secreting
various factors.11 A similar concept of niche also is considered
present and applies to CSCs which is the so called “cancer stem
cell niche (CSCN)”, and the interactions of CSCs with this niche
should be essential to maintain the CSC population.12 Cells within
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the CSCN secrete factors, which stimulate CSC self-renewal, induce
the differentiation such as angiogenesis13 and recruit immune
cells and other stromal cells, which secrete additional factors to
promote tumour cell invasion and metastasis.14 The niche for liver
CSCs has not yet been elucidated and still obscure, but the
mechanisms similar to those of the niche of the normal stem cells
should exist to control cell proliferation, migration, invasion and
apoptosis resistance.15
Recently, stem cells, including embryonic stem cells (ESCs) or
induced pluripotent stem cells (iPSCs), have gathered great
attention in the field of medicine because of the development
of novel therapy of tissue regeneration. On the other hand, the
development of CSCs or cancer cells could be possible when
normal stem cells are affected by the tumour microenvironment,
although the mechanism of development is not clear yet. Our
group hypothesises that the CSCs may appear from the normal
stem cells affected by the cancer-inducing niche defined as
chronic inflammation.16 This mechanistic insight, which converts
stem cells into liver CSCs, will significantly be important to
uncover the molecular mechanisms lying in liver CSC develop-
ment. In the present study, we tried to develop liver CSCs
converting from miPSCs using the conditioned medium (CM) of
HCC cell lines mimicking chronic liver disease.
METHODS
Cell culture
Human HCC cell line Huh7 (Riken Cell Bank, Japan) was cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich, USA)
supplied with 10% foetal bovine serum (FBS) and 100 U/mL
penicillin/streptomycin (Wako, Japan). Then cells were incubated
in a 37 °C incubator with 5% CO2. Medium was changed at 80%
confluence to 5% FBS. Culture supernatant, which is known as CM,
was collected after 48 h and centrifuged for 10 min at 1000 rpm at
room temperature and then filtered through a 0.22 μm filter
(Millipore, Ireland). Then 3mL CM were added into 3.5 cm dish
overnight to confirm that there were no surviving cancer cells in
CM. Mouse iPSCs (miPSCs) were maintained under the humidified
5% CO2 atmosphere at 37 °C on feeder layer of mitomycin-C-
treated mouse embryonic fibroblasts (Reprocell, Japan) in miPS
medium (DMEM containing 15% FBS, 0.1 mM non-essential amino
acid (NEAA), Thermo Fisher Scientific, USA), 2 mM L-Glutamine
(Nacalai Tesque, Japan), 0.1 mM 2-mercaptoethanol (Sigma-
Aldrich, USA), 1000 U/mL leukaemia inhibitory factor (LIF) (Merck
Millipore, USA) and 100 U/mL penicillin/streptomycin (Wako,
Japan). After 1 week, miPSCs were transferred to gelatine
(Sigma-Aldrich, USA) coated dishes. After 70% confluence, miPSC
conversion was started using 1:1 ratio of miPS medium and CM
from Huh7 cells for 4 weeks. The converted cells established from
miPSCs in the CM for 4 weeks were named as miPS-Huh7cm cells.
Using this method, we made three independent miPS-Huh7cm
cell lines. Nanog-GFP reporter expression was used in miPSCs and
the expression of green fluorescent protein (GFP) reflects the
maintenance of stemness. For primary culture, tumour tissues
were cut into small pieces in Hank’s Balanced Salt Solution (HBSS).
Then these were suspended into a 15-ml tube containing 50%
HBSS and 50% of dissociation buffer (0.25% trypsin, 0.1%
collagenase, 20% KnockOut™ Serum Replacement (Gibco, NY,
USA), 1mM of CaCl2 in phosphate-buffered saline (PBS)) and
incubated at 37 °C for 1 h. After digestion, the suspension was
mixed well using 1mL pipette and then waited for 5min until large
pieces settled down. The supernatant was transferred to a new tube
containing 1mL 10% FBS medium to stop digestion. The cellular
suspension was centrifuged at 300 rpm for 3min, and then the
supernatant was transferred again to a new tube that was
centrifuged at 1000 rpm for 10min. The cell pellet was then placed
in an appropriate volume of miPS medium without LIF, and the cells
were seeded into a dish at a density of 1 × 105/mL. These primary
cells were named as miPS-Huh7cmP1 cells. Cell morphology was
observed and photographed using Olympus IX81 microscope
equipped with a light fluorescence device (Olympus, Japan).
Tumorigenicity assay in vivo
To explore the tumorigenic capacity, mice were euthanised with
2% isoflurane through inhalation and liver orthotopic injections
were performed into 4-week-old Balb/c-nu/nu female immuno-
deficient mice (3 mice for each cell line; Charles River, Japan) with
0.5 × 106 cells suspended in 50 μL HBSS (Gibco, Japan). Tumour
formation was monitored weekly after implantation. After 4 weeks,
animals were sacrificed by euthanasia with 5% of isoflurane
through inhalation to ensure rapid loss of consciousness and
respiratory and cardiac arrest followed by cervical dislocation to
ensure the death of mice. To investigate the metastatic potential
of our novel cells, tail vein injection was performed into 4-week-
old Balb/c-nu/nu female immunodeficient mice (n= 3; Charles
River, Japan) with 5 × 106 cells suspended in 100 μL HBSS (Gibco,
Japan). Mice were monitored for up to 6 weeks. Animals were
sacrificed after 6 weeks. The plan of animal experiments was
reviewed and approved by the ethics committee for animal
experiments of Okayama University under the IDs OKU-2013252
and OKU-2016078. All animal experiments have been performed
in accordance with the ARRIVE/NC3R guidelines.
Histological analysis
Haematoxylin and eosin staining. Tumours were fixed in 10%
formalin (Wako Japan), embedded in paraffin wax and sectioned
for histologic examination at 5 μm. Sections were stained with
haematoxylin 0.5% (Sigma-Aldrich, USA) and eosin Y (Sigma-
Aldrich, USA). Slides were analysed using a light microscope
(Eclipse Ti, Japan).
Immunohistochemistry (IHC). IHC performed was the same as
standard procedures using the ABC reagent (Vector Laboratories,
USA). Detection was accomplished using DAB substrates (Vector
Laboratories, USA). Incubation of sections with PBS served as
negative controls. Sections were lightly counterstained with
haematoxylin and mounted with Micromount (Leica Camera AG,
Wetzlar, Germany).
Quantitative reverse transcription PCR (RT-qPCR)
The total RNA was isolated from the cells or tissues using TRIzol (Life
technologies, USA), according to the manufacturer’s protocol. The
extracted RNA was treated with DNase I (Promega, USA). One μg of
RNA was reverse transcribed using GoScript™ Reverse Transcription
System (Promega, USA). RT-qPCR assays were done by Light Cycler
480 II using Light Cycler 480 SYBR green I Master Mix (Roche
Diagnostics GmbH, Germany) according to the manufacturer’s
instructions. Gene expression level was normalised to that of
glyceraldehyde-3-phosphate dehydrogenase mRNA. The primers
used for the RT-qPCR analysis are listed in Supplementary Table S1.
RNA-seq library construction and sequencing
Isolation of total RNA was performed using TRIzol (Life technol-
ogies, USA). RNA samples were prepared using Illumina TruSeq
RNA Sample Preparation Kit and Illumina HiSeq 2500 was used to
sequence samples. Bioinformatics analysis was carried out by
Fligen, INC. (Novogene, Nagoya Japan).
Flow cytometry
Cells were incubated in PBS containing 10% FBS with either
fluorescence-conjugated primary antibody or primary antibody
followed by secondary antibody (Table S2). Cells were washed and
resuspended in PBS containing 10% FBS and analysed by BD
AccuriTM C6 plus flow cytometer (Becton & Dickinson, USA). The
data were analysed using the FlowJo® software (FlowJo, LLC,
Ashland, OR, USA).
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For spheroids initiated with CSCs, serum-free medium, DMEM,
supplied with NEAA (1%), L-glutamine (1%), 100× penicillin/
streptomycin (0.5%), β-mercaptoethanol (β-ME; 0.1 mM) and Insu-
lin-Transferrin-Selenium-Ethanolamine (ITS-x) (1/100 v/v) were
used for hanging drop method. Cells were suspended in medium
to get cell density of 2.5 × 104 cells/mL. Each hanging drop
contained 20 μL of volume, and the bottom dish contained 10mL
PBS. Dishes were incubated at 37 °C in 5% CO2 for 3 days, then
formed spheres were transferred to non-coated dish and analysed.
Limiting dilution assay
Cells were washed and subjected to enzymatic dissociation. To
investigate the percentage of single cells capable of forming new
spheres, cells were resuspended in serum-free medium supplied
with serum-free medium, DMEM, supplied with NEAA (1%), L-
glutamine (1%), 100× penicillin/streptomycin (0.5%), β-ME
(0.1 mM) and ITS-x (1/100 v/v) and seeded at dilution 500, 200,
100, 10 and 1 cell in 96-well low-attachment plates (EZ Bind Shut
TMSP, Japan). After 7 days of stem cell incubation, the frequency
was calculated with the software available at http://bioinf.wehi.
edu.au/software/elda/index.html.
In vitro tube-formation assay
Cells, 5 × 105 cells, were collected, resuspended in endothelial
basal medium EBM2 media (EBM-2 Single Quots Kit, Lonza,
Switzerland) and seeded in 12-well plates coated with growth
factor-reduced Matrigel (Corning Inc., Corning, USA) for 24 h in the
presence or absence of angiogenic factors (human epidermal
growth factor (5 ng/mL), vascular endothelial growth factor (VEGF;
0.5 ng/mL), R3-insulin-like growth factor-1 (20 ng/mL), ascorbic
acid (1 µg/mL), hydrocortisone (0.2 µg/mL), human basic fibroblast
growth factor (FGF; 10 ng/mL), heparin (22.5 µg/mL) and FBS
(0.02 mL/mL)). Experiments were performed in triplicate. Images of
formed tubes were captured by Olympus IX81 microscope
(Olympus, Japan).
Immunofluorescence
For immunofluorescence analysis, after incubation, cells were
washed with PBS, fixed with 4% paraformaldehyde for 20 min at
room temperature and subsequently permeabilised with 100%
methanol. The cells were incubated in blocking solution (PBS
supplemented with 10% FBS) for 1 h followed by incubation
overnight at 4 °C with the primary antibody (Table S2). Then cells
were washed and incubated with the secondary antibody. After
removal and proper washing of secondary antibody, nuclei were
counterstained with 4, 6-diamino-3-phenylidole dihydrochloride
(Sigma-Aldrich, USA) and mounted on glass sides using Vecta-
shield mounting medium (Vector Labs, USA). Images were taken
by Olympus IX81 inverted microscope.
Scratch wound-healing assay
Cells were seeded in 60-mm dishes at 5 × 105 cells/dish and
incubated for a 24-h period in miPS media to allow formation of a
confluent monolayer. The miPS media was removed and the
confluent cell sheet was wounded through scratching the culture
well surface with a 200 μL pipette tip. The scratch-wounded cells
were washed three times with PBS to remove any cell fragments
or detached cells before incubating in fresh media for 48 h. Cell
migration was monitored, and images of wound healing were
captured by using the microscope after 24 and 48 h.
Cell invasion assay
Cell invasion potential was evaluated using a Corning Matrigel
Invasion Chamber (Corning Inc., USA), which consisted of a
Matrigel-coated transwell and transwell inserts. First of all, inserts
were coated with ice-cold growth factor-reduced Matrigel and
incubated at 37 °C for at least 2 h. Then 5 × 104 cells were
suspended in 500 μL serum-free medium, DMEM, seeded onto the
insert, and 750 μL medium supplemented with 15% FBS was
added to the lower chamber. After incubation for 72 h in 5% CO2
atmosphere at 37 °C, non-invasive cells were removed by wiping,
and cells that had invaded the Matrigel were fixed in 4%
paraformaldehyde (Nacalai Tesque, Japan) for 5 min and subse-
quently fixed in methanol (Wako, Japan) for 20 min. Cells were
stained with Azure EMB Giemsa (Merck Millipore, USA) and
quantitatively analysed under a light microscope.
Statistical analysis
Statistical analyses were performed with Prism 7 (Graph Pad
Software, USA) using one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test when ANOVA
indicated a statistical significance existed with p < 0.05 indicating a
statistically significant difference. All experiments were sum-
marised as mean ± SD.
RESULTS
miPSCs survived in the presence of CM of hepatocyte-derived
carcinoma cell line Huh7 cells
Usually, iPSCs are considered to be induced progenitor cells,
which differentiate into various normal phenotypes, just like ESCs,
depending on the normal niche. On the other hand, cancer-
inducing niche could be conceivable as chronic condition. In this
study, we tried to differentiate miPSCs into liver CSCs using the
CM from HCC cell line Huh7 cells, which exhibited significant
expression of liver cancer markers, such as glypican 3, alpha
fetoprotein (AFP) and arginase 1 genes, without any genetic
manipulation and keeping serial transplantation of primary
cultures in the liver. Simultaneously, Huh7 cells were found by
gene expression meta-analysis using ExAtlas17 to be overexpres-
sing inflammatory-related secretory factors, such as interleukin-18,
C-X-C chemokine motif ligands 1, 5, 6, FGF-19, bone morphoge-
netic protein 2 and thrombospondin 4 when compared with PLC/
PRF/5 and/or Hep G2 cells (Supplementary Fig. 1). We supposed
that the CM from Huh7 cells could be available to mimic chronic
inflammation as the microenvironment of miPSCs. As the result,
miPSCs survived in the presence of CM of Huh7 cells instead of LIF
for 4 weeks, while miPSCs cultured without LIF differentiated and
stopped growing by losing GFP expression during the first week
(Supplementary Fig. 2). The survived miPSCs treated with CM were
named miPS-Huh7cm cells.
miPS-Huh7cm cells exhibited high tumorigenicity with liver CSC
signature
To evaluate the ability to form malignant tumours in vivo, 5 × 105
of miPS-Huh7cm cells were injected into the liver. miPS-Huh7cm
cells gave rise to 9 malignant tumours out of 9 mice after 28 days
of injection (Fig. 1a), while untreated miPSCs gave rise teratoma-
like phenotype with various germ layers (Supplementary Fig. 3).
Tumours were excised and partly cultured on gelatine-coated
dish in miPS medium to obtain the primary culture. From the
primary culture, which exhibited GFP-expressing colonies sur-
rounded by the progenies of myofibroblast-like cells, GFP
expressing puromycin-resistant cells were selected and named
as miPS-Huh7cmP1 cells (Fig. 1a).
Histology of miPS-Huh7cm cell-derived tumours showed that a
substantial portion of the tumours expressed a malignant
phenotype such as high nuclear-to-cytoplasmic ratio and mitotic
figures (Fig. 1b). Simultaneously, IHC of the tumours showed high
Ki-67 expression, which indicated high proliferation rate, and GFP
expression, which indicated undifferentiated cell population
derived from miPSCs (Fig. 1c). IHC also showed positive staining
for E-cadherin and Vimentin implying the presence of hetero-
geneous cell phenotypes in the miPS-Huh7cm cell-derived
malignant tumours. Protein expression was quantitated using
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Fig. 1 Tumorigenicity of miPSCs treated with the conditioned medium of Huh7 cells. a Representative scheme of the orthotopic injection of
miPS-Huh7cm cells (miPS treated with Huh7cm for 4 weeks) into the liver and the formed tumour after 4 weeks of injection. Scale bars represent
100 and 50 µm. b Histopathological features of the primary tumours were evaluated by H&E staining, showing the presence of mitotic figures
(white cycle). Scale bars represent 64, 32 and 16 µm. c Immunostaining of the malignant tumours for Anti-ki67 Ab, Anti-GFPAb, Anti-E-Cadherin Ab
and Anti-Vimentin Ab; and histogram showing area of immunopositive cells of each marker. All data were from three independent experiments
(n= 3). Scale bars represent 64 μm. d RT-qPCR analysis for liver cancer-associated biomarkers in the derived tumour tissue compared to liver. All
data were from three independent experiments (n= 3) (***p < 0.0001, ****p < 0.00001). e RT-qPCR analysis of CSC markers in the derived tumour
tissue compared to liver. All data were from three independent experiments (n= 3) (***p < 0.0001, ****p < 0.00001).
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the Image J software for those markers and showed that
approximately 30% of tumour sections expressed Ki67 and GFP
while Vimentin was 70% and E-Cadherin was 20%.
AFP, GPC-3 and CK19 are considered as biomarkers of
malignant liver tumour18–20 and the combination of these markers
improves the accuracy of diagnosis. Using RT-qPCR analysis, we
found statistically significant overexpression of these biomarkers
in miPS-Huh7cm cell-derived tumour tissues. The relative amount
of mRNA expression was enhanced by 16-, 18- and 100-folds for
CK19, AFP and GPC3 genes, respectively, when compared to
normal mice liver as control (Fig. 1d). Simultaneously, the
expression of CSC markers in the tumour tissues were enhanced
by 30-, 150- 200-folds for CD24, CD133 and CD44, respectively,
when compared to miPSCs (Fig. 1e).
To further confirm the molecular analysis of the CSCs derived
from miPSCs, RNA-sequencing was performed. The expression of
liver cancer-related markers such as AFP and Arg1 were found to
change significantly together with liver progenitor network genes
such as Hnf1a, Hnf1b, Foxa1, Hnf4a, Foxc1, Foxc1, Foxq1 and Hes1
as well as main oncogenes and liver CSC markers implicated such
as CD44, CD47, Cxcl12, Lcn2, Lyz2, CDKN1A, Mapk3, Cdh13, Cxcl14,
Cxcl16, Il11 and Il33. The expression level changes as shown in the
heat map (Fig. 2a) suggest the possible roles of those genes in
liver CSC development and could explain the functions of those
gene in liver cancer progression. Moreover, the expression level of
stem cell marker genes such as Nanog, Sox2, Klf-4 and Oct-4
transcription factors in miPS-Huh7cm and miPS-Huh7cmP1 cells
showed that both cells sustain stemness property (Fig. 2b).
To further confirm that the miPS-Huh7cmP1 cells were enriched
with the cells expressing liver cancer-associated markers (AFP,
GPC3 and CK19) and CSC markers (CD44, CD133 and CD24), we
examined the gene expression levels compared to those in
miPSCs and miPS-Huh7cm cells. Liver cancer-associated and CSC
markers, as expected from the results of the analyses of tumour
tissue (Fig. 1d), showed significant elevation again in miPS-
Huh7cmP1 cells when compared to miPSCs (Fig. 2c).
Using flow cytometry, we further confirmed the expression of
liver cancer-associated markers such as AFP, GPC3 and carcinoem-
bryonic antigen (CEA) in miPS-Huh7cmP1 cells in comparison with
Nanog (Fig. 2d). AFP was detected in only 1% of the cells
suggesting that the cells are still undifferentiated as liver cancer
cells independent of Nanog expression. More than 40% of the
cells were CEA+/Nanog+ suggesting that CEA could be a marker
of early stage of differentiation. In contrast with these two
markers, GPC3 expression does not appear correlated with Nanog
expression. In some populations (24%), GPC3 expression was not
showing up with the decrease of Nanog expression while in other
population (15%) GPC3 expression showed up while Nanog was
still positive (Fig. 2d). Collectively, GPC3 expression should be an
intermediate marker among the three markers.
Tumorigenic potential of miPS-Huh7cm cells was kept during
serial orthotopic transplantation
To confirm that miPS-Huh7cm cells maintained tumorigenic
potential, serial transplantations of the primary cultures were
evaluated for tumour formation. The secondary tumour was
obtained by orthotopically injecting 5 × 105 miPS-Huh7cmP1 cells,
which were the primary cells from the miPS-Huh7cm-derived
tumour, into the liver (Supplementary Fig. 4a). Similarly, the third
tumour was obtained by injecting 5 × 105 miPS-Huh7cmP2 cells to
get primary cells of miPS-Huh7cmP3 cells. Simultaneously,
tumour-derived cells were maintained by orthotopically trans-
planting tumour tissue minced into 1–3mm diameter.
The tumours developed by the second and the third injection
spread in different lobes of the liver even only after 3 weeks of
injection. Existed tumours exhibited the phenotypes of malig-
nancy such as multiple pathological mitotic figures, glandular
epithelial hyperplasia, varying cell sizes, irregular cell forms, high
nuclear-to-cytoplasmic ratio and severe nuclear atypia (Supple-
mentary Fig. 4b). From these results, we concluded that the
orthotopic malignant liver cancer model was successfully estab-
lished with the injection of miPS-Huh7cm cells and the primary
cultured cells (miPS-Huh7cmP1 and miPS-Huh7cmP2).
The liver CSC signatures were enhanced under liver environment
in vivo
Liver CSC signatures were evaluated to be maintained in miPS-
Huh7cm cells keeping tumorigenic potential during the serial
transplantation. The malignant tumour tissues from the three
injections (Fig. 3a) were further analysed for the liver CSC
signature. First, the expression levels of liver cancer-associated
markers, AFP, GPC3 and CK19 as well as liver CSC markers, CD44,
CD24 and CD133, in malignant tumours were relatively high
compared to that in normal liver by RT-qPCR (Fig. 3b). AFP
expression increased significantly (p ≤ 0.01) by 19-, 50- and 14-
folds in first, second and third tumours, respectively, when
compared to normal mice liver. GPC3 was found significantly
(p ≤ 0.01) overexpressed in all tumours by 68-, 50- and 96-folds in
first, second and third tumours, respectively. CK19 was also
elevated in all tumours by 17-, 76- and 11-folds in first, second and
third tumours, respectively.
Second, liver CSC phenotypes were immunohistochemically
assessed in the primary tumours derived from miPS-Huh7cm cells
injected into the liver. Immuno-reactive liver cancer markers AFP,
GPC3 and CK19 were positively stained as well as the CSC markers
such as CD44, CD24 and CD133 in the tumour tissue developed in
the liver (Fig. 3c). Protein expression was quantitated using the
Image J software for those markers and showed that approxi-
mately 50% of tumour sections expressed AFP and CK19 while for
GPC3 it was 20% and for CD44 it was 30% (Fig. 3c). Finally, single-
cell suspension from tumour tissues was subjected to flow
cytometry to assess the liver CSC markers, such as AFP, GPC3,
CEA and CD44 (Fig. 3d). The result showed the presence of
subpopulations that were double positive for AFP+/CD44+,
GPC3+/CD44+ and CEA+/CD44+. Among the AFP+ subpopula-
tions, two populations of AFP+/CD44− (23.8%) and AFP+/CD44+
(18.8%) were present while AFP−/CD44+ was found to be 6.94%.
As for the GPC3+ subpopulations, two populations GPC3+/CD44−
(44.3%) and GPC3+/CD44+ (18.3%) were found. For CEA+
subpopulations, there were two subpopulations: one was CEA+/
CD44− (15.5%) and another was CEA+/CD44+ (7.7%). These results
indicate that miPS-Huh7cm cells successfully differentiated to
exhibit liver CSC characters after injection into the liver providing
malignant tumours with the markers of liver CSCs as well as those
well accepted as liver cancer markers.
The primary cultures from serial transplantation exhibited GFP-
expressing colonies surrounded by myofibroblast-like cells indi-
cating that serial transplantation maintained the presence of CSCs
(Supplementary Fig. 5a). The expression of liver cancer markers
was compared between all primary cultured cells derived from the
serial transplantation (miPS-Huh7cmP1, miPS-Huh7cmP2 and
miPS-Huh7cmP3 cells) and miPS-Huh7cm cells compared to
normal liver while the expression of liver CSC markers was
compared to miPSCs (Supplementary Fig. 5b). The expression of
GPC3 and CK19 was found significantly upregulated in the primary
cultured cells when compared to normal liver while the expression
of AFP was downregulated. CD44 expression in the primary
cultured cells was extremely elevated in miPS-Huh7cmP2 and
miPS-Huh7cmP3 cells by 100- and 275-folds, respectively, when
compared to miPS. The expression of CD24 and CD133 was
significantly elevated at the same time indicating the CSC
characters. Collectively, these data suggest that serial transplanta-
tion helps maintaining the presence of liver CSCs as the core
population in vivo.
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Fig. 2 Characterisation of the primary culture of the tumour cells derived from miPS-Huh7cm cells injected into the liver.
a Representative cluster analysis among miPS, miPS-Huh7cm cells and miPS-Huh7cm P cells (left). The colour range represents the log10
(FPKM+1) value from large (red) to small (blue). Main oncogenes and CSC markers implicated in liver cancer are enlarged (right). b Stemness
marker gene mRNA expression levels were analysed through RT-qPCR analysis in miPS-Huh7cm cells, and miPS-Huh7cm P cells were
compared to miPS (*p < 0.01, **p < 0.001, ***p < 0.0001, ****p < 0.00001). c Liver cancer stem cell marker gene mRNA expression levels
were analysed through RT-qPCR analysis in miPS-Huh7cm cells, and miPS-Huh7cm P cells were compared to miPS (**p < 0.001, ***p < 0.0001,
****p < 0.00001). d Flow cytometric analysis for liver cancer-associated markers such as GPC3, AFP and CEA with Nanog in miPS-Huh7cmP1
cells. Each result is shown as a representative of at least five independent experiments.
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Fig. 3 The liver CSC signatures were enhanced in vivo. a Representative images of tumour and H&E staining for first, second and third
primary orthotopic injection tumour sections. Scale bars represent 64 μm. b RT-qPCR analysis of AFP, GPC3 and CK19 were examined and liver
CSC markers such as CD133, CD44 and CD24 for the three malignant tumour tissues were compared to those in normal mice liver. Gene
expression levels were normalised to those of GAPDH (*p < 0.01, **p < 0.001, ***p < 0.0001, ****p < 0.00001). c Immunohistochemical staining
of formalin-fixed paraffin-embedded liver tumour tissue derived from serial transplantation (miPS-Huh7cm cells) and histogram showing area
of immunopositive cells of each marker. Samples representative of each tumour were stained with antibodies recognising AFP, GPC3 and
CK19. Also, antibodies recognising liver CSC like CD44, CD24 and CD133 were applied to the tumour tissues. All data were from three
independent experiments (n= 3). Scale bars represent 64 μm. d FACS analysis shows AFP+/CD44+, GPC3+/CD44+ and CEA+/CD44+
subpopulations in the tumour single-cell suspension.
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miPS-Huh7cm and miPS-Huh7cmP1 cells exhibited high self-
renewal potential
The self-renewal capacity of miPS-Huh7cm and miPS-Huh7cmP1
cells was assessed for further properties as CSCs. In adhesive
culture condition, both cells exhibited two different types of
populations; one was colony-expressing GFP and the other was
fibroblast-like cells attached to the bottom of dish without
expressing GFP (Fig. 4a). The ratio of GFP-positive and -negative
cells was estimated by flow cytometry. miPS-Huh7cm and miPS-
Huh7cmP1 cells contained GFP-positive cells at 27% and 35%,
respectively, while undifferentiated miPSCs were all GFP positive
(Fig. 4b). The undifferentiated GFP-positive cells were recog-
nised as sphere-forming population (Fig. 4c), while the GFP-
negative fibroblast-like cells could not survive in non-adhesive
condition of hanging drop, which would provide a small number
of cells such as CSCs with a three-dimensional isolated
suspension environment where they were maintained as
spheroids.21 miPS-Huh7cmP1 cells showed significantly high
spheroid-forming potential when compared to miPS-Huh7cm
cells or Huh7 cells. Also, the sphere size was larger in miPS-
Huh7cm P1 when compared to miPS-Huh7cm as well as Huh7
cells (Fig. 4d). This indicated that both cells had self-renewal
capacity. Extreme limiting dilution assay was performed to
further confirm the sphere-forming potential when low in
number. Results show that miPS-Huh7cmP1 cells exhibited the
potential at significantly lower number of cells when compared
to that of miPS-Huh7cm cells (Fig. 4e). Spheres derived from
miPS-Huh7cm and miPS-Huh7cmP1 cells were assessed for the
expression of Nanog and Oct 3/4 since Nanog and Oct 3/4 are
considered as critical factors to maintain the undifferentiated
state and self-renewal of stem cells.22 Both types of cells were
found to be positive for both markers (Fig. 4f). Collectively, the
self-renewal potential was confirmed in both miPS-Huh7cm and
miPS-Huh7cmP1 cells.
miPS-Huh7cm and primary cultured cells can differentiate into
vascular endothelial-like cells
Differentiation potential is another property of CSCs as well as self-
renewal. miPS-Huh7cm and miPS-Huh7cmP1 cells were assessed
for the potential to differentiate into endothelial-like cells forming
capillary-like tubes on Matrigel. Formation of capillary-like tubes
were confirmed by these cells indicating pro-angiogenic proper-
ties of miPS-Huh7cm and miPS-Huh7cmP1 cells in tumorigenesis
(Fig. 5a). Both cells showed high potential of tube formation even
without VEGF-A when compared to Huh7 or miPS-Huh7cm
puromycin-treated cells. miPS-huh7cmP1 cells showed significant
elevation in the number of branching points per field when
compared to miPS-Huh7cm, Huh7 and miPS-Huh7cm cells treated
by puromycin (Fig. 5b).
Since the results implied the possible role of miPS-Huh7cm and
miPS-huh7cmP1 cells in tumour angiogenesis, the expression of
vasculogenesis-associated factors such as VEGF-A, VE-cadherin
and platelet-endothelial cell adhesion molecule-1 (CD31) were
evaluated in both cells.23 As a result, both cells were found to
express VEGF-A but no significant difference was observed
between the expression levels in those cells in the adhesive
condition, which contained both differentiated and undifferen-
tiated cells, and that in undifferentiated population limited by
puromycin. On the other hand, significant difference in the
expression of VE-cadherin and CD31 genes were observed
between the two different conditions (Fig. 5c). Stained with anti-
CD31 antibody, the tubular structure derived from both cells
exhibited high expression of CD31 in both cells (Fig. 5d). Flow
cytometric analysis revealed the presence of subpopulation
positive for VE-cadherin (Fig. 5e). The expression of these
angiogenic factors and tube-formation assay results support the
differentiation potential of miPS-Huh7cm and miPS-Huh7cmP1
cells. The angiogenic potential of the cells may enhance the
concept of angiogenesis, which has been considered to play a
pivotal role in tumour growth.12,13,24
miPS-Huh7cm and primary cultured cells exhibited invasion and
migration capacity in vitro
In the past couple of years, scientists well accepted that CSCs have
critical role in metastasis.25,26 Steps in the metastatic cascade
involve the migration and invasion of the cells degrading the
extracellular matrix and cell-to-cell adhesion. The metastatic
potential of miPS-Huh7cm and miPS-Huh7cmP1 cells were
assessed in vitro by the scratch wound-healing assay for cell
migration and by the transmembrane assay for cell invasion. In the
scratch wound-healing assay, the motility of miPS-Huh7cmP1 cells
was significantly higher than that of miPS-Huh7cm cells (Fig. 6a,
b). The percentage of wound closure area after 24 h was 48% and
58% for miPS-Huh7cm and miPS-Huh7cmP1 cells, respectively,
while it was 82% and 100%, respectively, after 48 h.
As for the invasive capacity, cells were seeded onto Matrigel-
coated transwell membranes and the number of the cells invaded
to the other side of the filter was counted after 72 h (Fig. 6c). The
ability of invasion was higher in miPS-Huh7cmP1 cells than in
miPS-Huh7cm cells. Since Slug, matrix metalloproteinase 2
(MMP2) and MMP9 are considered to be responsible for invasion
and migration,27 the expression levels of the corresponding genes
in miPS-Huh7cm and miPS-Huh7cmP1 cells were assessed and
found to be significantly higher than those in miPSCs (Fig. 6d).
MMP9 was further confirmed by immunostaining (Fig. 6e). These
results suggest that the invasive ability of miPS-Huh7cm cells were
enriched during the tumour development in vivo.
Primary cultured cells exhibited metastatic potential in vivo
Primary culture cells (miPS-Huh7cmP1 cells) produced tumours
that grew in the lung after 6 weeks of cell injection into the tail
vein. Interestingly, the lungs of the mice with tumours showed
redness, swelling and large separated tumours with small parts of
normal lung suggesting that most of the lung were invaded by
metastasis (Fig. 6f). The primary culture from the metastatic parts
showed two different types of populations: one was expressing
GFP and the other was negative for GFP confirming that our cells
metastasised to the lung from tail vein injection. Indeed,
histopathological analysis of representative haematoxylin–eosin-
stained sections of metastasis in the lung showed malignant
phenotype with abnormal mitotic figures, cytoplasmic degenera-
tion and high nuclear-to-cytoplasmic ratio (Fig. 6g). This result
confirms the metastatic potential of our novel cells.
DISCUSSION
The presence of the heterogenous subpopulation of malignant
phenotypes in tumour tissues has been explained as one of the
concepts of CSCs.28 However, the origin of CSCs and the niche
required for CSC development are still unknown. The CSC
generation is the precondition for CSC research, which will help
to identify the process of CSC development as well as therapy.
Liver cancer is not an exception. Scientists have tried to
investigate the niche and molecular mechanisms of CSC devel-
opment in the liver cancer during the past couple of decades. The
development of CSC from iPSCs was described as the conversion
of iPSCs into CSC in the presence of CM derived from cancer-
derived cell lines.25 That was the first report in the light of the
conversion of stem cells into CSCs. The chronic inflammation has
been reported to have critical roles at different phases of tumour
development and might trigger the preliminary mechanism of the
tumorigenesis. Since the inflammation may enrich the production
of chemokines, cytokines and growth factors, it could induce
signal transductions for cell survival and proliferation with
chromosomal instability.29 This chronic situation might maintain
the induction of cellular alteration resulting in malignancy.30,31
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Fig. 4 Self-renewal potential of the CSC-like cells. a Representative images for adherent culture of Huh7, miPS-Huh7cm and miPS-
Huh7cmP1 cells. Scale bars represent 100 μm. b FACS analysis shows GFP population in miPS-Huh7cm and miPS-Huh7cmP1 cells. c Sphere-
formation assay in serum-free medium shows spherogenic potential of both miPS-Huh7cm and miPS-Huh7cmP1 cells compared to Huh7 cells.
Scale bars: 50 μm. d Number of spheres formed from miPS-Huh7cmP1 cells compared to miPS-Huh7cm and Huh7 cells. e Extreme limiting
dilution assay assessment of the limiting dilution sphere-forming potential of miPS-Huh7cm and miPS-huh7cmP1 cells. f Immunofluorescence
staining for Nanog and Oct 3/4 in tumour spheroid derived from miPS-Huh7cm and miPS-Huh7cmP1 cells. Scale bars represent 64 μm.
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Fig. 5 miPS-Huh7cm cells have the potential to differentiate into vascular endothelium-like cells. a Tube-formation assays in Huh7, miPS-
Huh7cm (Puro), miPS-Huh7cm and miPS-Huh7cmP1 cells after 24 h of culturing on Matrigel. Scale bars represent 50 μm. b The number of
branching points per field in miPS-Huh7cm and miPS-Huh7cmP1 cells compared to Huh7 and miPS-Huh7cm cells treated with puromycin.
c The expression levels of VEGF-A VE-cadherin and CD31 were quantified by RT-qPCR. Gene expression levels were normalised to those of
GAPDH (**p < 0.001, ***p < 0.0001). d Immunofluorescence staining was performed using anti-CD31 antibody in tubular structure derived
from miPS-Huh7cm and miPS-Huh7cmP1 cells. Data are the results of three independent experiments. Scale bars represent 50 μm. e The
population of VE-cadherin-positive cells in primary cells were quantified by flow cytometry. All data were from three independent
experiments (n= 3). miPS-Huh7cm cells (Puro): miPS-Huh7cm cells treated with puromycin.
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Thus we thought that the CM from cancer cells, which contains
various inflammatory cytokines and chemokines, should be
sufficient to induce CSC formation from miPSCs by mimicking
chronic inflammation, as we also reported that these pro-
inflammatory cytokines and chemokines are activating G
protein-coupled receptors and phosphoinositide 3-kinase path-
way leading to activate different transcription factors responsible














Slug MMP 2 MMP 9
miPS
miPS-Huh7 cm cells












































































Time after wounding (h)
miPS-Huh7 cm cells





Injection of miPS-Huh7 cm P1 cells











miPS-Huh7 cm cells  miPS-Huh7 cm P1 cells

















































32 µm 32 µm
32 µm32 µm
32 µm 32 µm
32 µm32 µm
32 µm 32 µm
A novel model of liver cancer stem cells developed from induced. . .
SM Afify et al.
1388
Here, in this study, we demonstrated for the first time that liver
CSCs could be generated from iPSCs by culturing in the presence
of HCC CM (Huh7) without any genetic manipulation. As a result,
we established a protocol to convert iPSCs into liver CSCs. After
4 weeks of culturing miPSCs in the presence of CM, CSCs were
induced as miPS-Huh7cm cells, which formed malignant tumours
in the liver after 28 days of injection into the liver. Primary cells
from the malignant tumour of miPS-Huh7cm cells exhibited the
properties similar to liver CSCs, which were defined by self-
renewal capacity, differentiation potential and tumorigenicity
in vivo.31 Converted cells, miPS-Huh7cm cells, were highly
tumorigenic and developed malignant tumours after 4 weeks
when injected into the liver. These malignant tumours showed
significant expression of the markers mostly common to liver
cancer such as AFP,33 GPC3,34 CEA35 and CK19.36 During the past
couple of years, a number of works have identified the
membrane-bound markers in liver CSCs. Initially, the characterisa-
tion of liver CSCs focussed also in liver cancer on the identification
of general CSC markers such as CD24,37 CD4438 and CD133,39
while CK19 was also reported to serve as a relatively specific
marker of liver CSCs.36 In our study, the malignant tumours
developed in the liver showed high and significant expression of
CD24, CD44 and CD133 when compared to miPSCs.
The primary cultured cells from all developed tumours showed
significant elevation of CSC markers and liver cancer-associated
biomarkers.
Taking the results of flow cytometric analysis, it seems that
there are different stages of differentiation in vitro from miPSCs up
to liver cancer cells with the intermediate stage of liver CSCs with
a comparable level of expressing markers. Even in the Nanog-
positive stage, the expression levels of liver CSCs could be
distinguished by the expression of CEA, GPC3 and AFP.
Our data propose five different stages of stem cells from miPSCs
up to liver cancer cells depending on the expression of a panel of
markers. Those stages are Nanog+/CEA−/GPC3−/AFP−, Nanog
+/CEA+/GPC3−/AFP−, Nanog+/CEA+/GPC3+/AFP−, Nanog
+/CEA+/GPC3+/AFP+ and Nanog−/CEA+/GPC3+/AFP+. From
these hypothesised stages, an individual marker does not seem to
be sufficient to specify liver CSCs. At the same time, it is worthwhile
noticing that the undifferentiated stage of CSCs could be
distinguished if a panel of markers was used (Supplementary Fig. 6).
Converted cells, miPS-Huh7cm cells, and the tumour-derived
primary cells sustained the expression of stemness markers such
as Nanog, Sox2, Kif4 and Oct 3/4, which are considered essential
for maintaining cell stemness.40 These transcription factors related
to pluripotency may also contribute to tumorigenesis.41 On the
other hand, the angiogenesis could be one of the differentiation
potentials of CSCs resulting in the differentiation into CD31-
positive endothelial cells with expression of VEGF-A and VE-
cadherin. Simultaneously, miPS-Huh7cm and the tumour-derived
primary cells showed high potential of sphere formation at very
limited dilutions as self-renewing character.
Furthermore, metastatic potential should be conceivable to find
the expression of MMP2 and MMP9, which are closely associated
with the epithelial-to-mesenchymal transition. Collectively, we
have successfully demonstrated the preparation of liver CSCs by
converting miPSCs in the presence of the CM derived from human
liver cancer cell line Huh7 cells.
The liver CSCs converted from miPSCs suffice the definitions
of CSCs as well as those of the liver cancer. Not only in the
culture containing CM from liver cancer-derived cells but also
the tumour formation in the liver tissue enhanced the character
of liver CSCs in converted cells. The factors critically related
to the liver microenvironment appear to be responsible for the
CSC-inducing event observed in the induction of liver CSCs. This
process of establishing CSC model42 will be useful for under-
standing the induction process of different CSCs in the future.
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